spacer
home > ebr > spring 2003 > fast track project implementation: risk or reward?
PUBLICATIONS
European Biopharmaceutical Review

Fast Track Project Implementation: Risk or Reward?

New technology products, particularly those with a long regulatory approval time, often come under extreme pressure in the industrialisation stage - taking the product from bench or small scale up to full manufacturing scale. Key to success are project definition, risk management, effective teamwork and supply chains, and controlled handover and validation.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Gareth Davies, Operations Director at CEL International

Gareth Davies is Operations Director with CEL International in Coventry. A Chemist by training, Gareth has a process operational background and over 15 years' experience in projects ranging from £1/2 million to £140 million and in diverse applications from biotechnology through pharmaceuticals and food production to man-made fibres and chemicals. A core member of the recent task group sponsored by the Department of Trade and Industry to define best practice for fast track projects, Gareth led CEL's teams on the 2001 and 2002 ACTIVE 'Project of the Year' projects, the latter having been won against pan-European competition.

spacer
Gareth Davies
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

BIO-Europe Spring® 2012 — 6th International Partnering Conference

19-21 March 2012, Amsterdam RAI Convention Center, Amsterdam, The Netherlands

BIO-Europe Spring is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe, and continues the tradition of providing life science companies with high caliber partnering opportunities. Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups.  
More info >>

 
News and Press Releases

Norwich Expands Capabilities for Phase I-III Clinical Trials

Norwich Clinical Services (NCS), a global provider of clinical research services for the pharmaceutical and biotech industries, today announced a significant expansion to its clinical research capabilities in order to meet growing market demand. Primary to the expansion, NCS unveiled a new clinical facility with capabilities to conduct all aspects of Phase I – III clinical trials including pharmacokinetics in healthy volunteers, bio-availability and bio-equivalence studies, drug metabolism studies, dose proportionality studies and multiple dose studies.
More info >>

 

 

Buy Atrovent Online no prescription Buy Symbicort Online no prescription Buy Flovent Online no prescription Buy Flonase Online no prescription Buy Rhinocort Online no prescription Buy Allegra Online no prescription Buy Advair Online no prescription Buy Combivent Online no prescription Buy Astelin Online no prescription Buy Spiriva Online no prescription Buy Ventolin Online no prescription
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement
.